On ECHEMI
Home > Drugs > Hainan Sanye Pharmaceutical Factory Co., Ltd.
Hainan Sanye Pharmaceutical Factory Co., Ltd.
  • Founded in:

    1989-01-19
  • Country:

    China China
  • Address:

    No. 6, Sanye East Road, Longhua District, Haikou City, Hainan Province
  • Tax NO.:

    914600002012496387
  • Registered Funds:

    10 million yuan
  • Email:

Related Drugs
Cefaclor Dry Suspension
Cefaclor
Name Description Content CAS NO. Registered Holders
Cefaclor

This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, grass-green streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2-4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 9-8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

More

This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, grass-green streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2-4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 9-8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

53994-73-3 28
Cefaclor Dry Suspension
The main chemical component is cefaclor: (6R,7R)-7-[(R)-2-amino-2-phenylacetylamino]-3-chloro-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monohydrate
Name Description Content CAS NO. Registered Holders
Cefaclor

This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

More

This product is a broad-spectrum semi-synthetic cephalosporin antibiotic. Its activity against penicillinase-producing Staphylococcus aureus, group A hemolytic streptococci, viridans streptococci and Staphylococcus epidermidis is the same as that of cefadroxil, and its antibacterial effect against non-enzyme-producing Staphylococcus aureus and pneumococci is 2 to 4 times stronger than that of cefadroxil. Its activity against Gram-negative bacilli, including Escherichia coli and Klebsiella pneumoniae, is stronger than that of cefadroxil, and is similar to that of cefadroxil. Its activity against Proteus mirabilis, Salmonella and Shigella is stronger than that of cefadroxil. 2.9 to 8 mg/L of this product can inhibit all Haemophilus influenzae, including strains resistant to ampicillin. Moraxella catarrhalis and Neisseria gonorrhoeae are very sensitive to this product. Indole-positive Proteus, Serratia, Acinetobacter and Pseudomonas aeruginosa are all resistant to this product. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls.

53994-73-3 28
Cefpodoxime Proxetil Tablets
The main ingredient of this product is cefpodoxime axetil, whose chemical name is: (6R,7R)-7-[2-(2-aminothiazol-4-yl)-2-(Z)-(methoxyimino)-acetamido]-3-methoxymethyl-8-oxo-5-thio-1-azabicyclo-[4,2,0]oct-2-ene-2-carboxylic acid isopropyloxycarbonyloxyethyl ester.
Name Description Content CAS NO. Registered Holders
Cefpodoxime proxetil

Cefpodoxime proxetil is an oral broad-spectrum third-generation cephalosporin. After entering the body, it is hydrolyzed into cefpodoxime by nonspecific esterase to exert antibacterial effects. It is effective against both Gram-positive and Gram-negative bacteria. It achieves bactericidal effects by inhibiting the biosynthesis of microbial cell walls. It is stable to beta-lactamase and is still sensitive to many beta-lactamase-producing microorganisms that are resistant to penicillin and cephalosporins. It is ineffective against some ultra-extended-spectrum beta-lactamases.

More

Cefpodoxime proxetil is an oral broad-spectrum third-generation cephalosporin. After entering the body, it is hydrolyzed into cefpodoxime by nonspecific esterase to exert antibacterial effects. It is effective against both Gram-positive and Gram-negative bacteria. It achieves bactericidal effects by inhibiting the biosynthesis of microbial cell walls. It is stable to beta-lactamase and is still sensitive to many beta-lactamase-producing microorganisms that are resistant to penicillin and cephalosporins. It is ineffective against some ultra-extended-spectrum beta-lactamases.

87239-81-4 28
Roxithromycin Capsules
Active ingredient: Roxithromycin.
Name Description Content CAS NO. Registered Holders
Roxithromycin

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, but stronger than erythromycin against Legionella pneumophila. Its antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P site), blocking the transfer RNA (t-RNA) from binding to the P site, and also blocking the transfer of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.

More

This product is a semi-synthetic 14-membered macrolide antibiotic. Its antibacterial spectrum and antibacterial effect are basically similar to those of erythromycin. It is slightly less effective than erythromycin against Gram-positive bacteria, but stronger than erythromycin against Legionella pneumophila. Its antimicrobial effect against Chlamydia pneumoniae, Mycoplasma pneumoniae, and Ureaplasma urealyticum is similar to or slightly stronger than that of erythromycin. This product can penetrate the bacterial cell membrane and reversibly bind to the 50S subunit of the bacterial ribosome near the donor (P site), blocking the transfer RNA (t-RNA) from binding to the P site, and also blocking the transfer of the polypeptide chain from the acceptor site (A site) to the P site, thereby inhibiting bacterial protein synthesis.

80214-83-1 28
Penicillin V Potassium Tablets
The main ingredient of this product is penicillin V potassium. Chemical name: (2S, 5R, 6R)-3,3-dimethyl-7-oxo-6-(2-phenoxyacetylamino)-4-thia-1-azabicyclo[3.2.0]-heptane-2-carboxylic acid potassium salt. Molecular weight: C16H17KN2O5S
Name Description Content CAS NO. Registered Holders
Penicillin V potassium salt

This product is a penicillin antibiotic. The antibacterial spectrum is the same as penicillin. It has antibacterial activity against most Gram-positive bacteria, Gram-negative cocci, individual Gram-negative bacilli (such as Haemophilus), spirochetes and actinomycetes, but most Staphylococcus strains (>90%) including Staphylococcus aureus and coagulase-negative Staphylococci can produce beta-lactamase to hydrolyze this product and inactivate it. The activity of this product against most sensitive strains is 2 to 5 times weaker than that of penicillin. It has no antibacterial effect on strains that produce penicillinase. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls, causing the bacteria to rupture and dissolve rapidly.

More

This product is a penicillin antibiotic. The antibacterial spectrum is the same as penicillin. It has antibacterial activity against most Gram-positive bacteria, Gram-negative cocci, individual Gram-negative bacilli (such as Haemophilus), spirochetes and actinomycetes, but most Staphylococcus strains (>90%) including Staphylococcus aureus and coagulase-negative Staphylococci can produce beta-lactamase to hydrolyze this product and inactivate it. The activity of this product against most sensitive strains is 2 to 5 times weaker than that of penicillin. It has no antibacterial effect on strains that produce penicillinase. The mechanism of action of this product is to inhibit the synthesis of bacterial cell walls, causing the bacteria to rupture and dissolve rapidly.

132-98-9 18
Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.